Dexcom (DXCM) Capital Expenditures (2010 - 2026)

Dexcom (DXCM) has reported Capital Expenditures for 17 consecutive years, with $84.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 9.99% year-over-year to $84.7 million in Q2 2026; TTM through Jun 2026 was $343.7 million, a 17.56% decrease from a year earlier, with the FY2025 full-year figure at $363.5 million, up 1.31% from the prior year.
• Capital Expenditures was $84.7 million for Q2 2026 at Dexcom, up from $76.6 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $124.6 million in Q4 2024 and troughed at $50.4 million in Q3 2023.
• A 5-year average of $82.5 million and a median of $82.6 million in 2025 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures slumped 53.42% in 2023 and surged 137.33% in 2024, its largest moves.
• Over 5 years, Capital Expenditures stood at $63.5 million in 2022, then retreated by 17.32% to $52.5 million in 2023, then surged by 137.33% to $124.6 million in 2024, then declined by 18.22% to $101.9 million in 2025, then declined by 16.88% to $84.7 million in 2026.
• The last three Capital Expenditures figures came in at $84.7 million (Q2 2026), $76.6 million (Q1 2026), and $101.9 million (Q4 2025), per Business Quant data.